Immunovant Inc
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating p… Read more
Immunovant Inc (IMVT) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.094x
Based on the latest financial reports, Immunovant Inc (IMVT) has a cash flow conversion efficiency ratio of -0.094x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-92.33 Million) by net assets ($986.13 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Immunovant Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Immunovant Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Immunovant Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immunovant Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hillenbrand Inc
NYSE:HI
|
-0.019x |
|
Viscofan
MC:VIS
|
0.066x |
|
NET ONE SYSTEMS
MU:NOX
|
N/A |
|
The Andersons Inc
NASDAQ:ANDE
|
-0.005x |
|
Van Lanschot NV
AS:VLK
|
0.878x |
|
THK Co. Ltd
PINK:THKLF
|
0.025x |
|
Greif Bros Corporation
NYSE:GEF
|
-0.008x |
|
FOUR CORNERS PROPERTY TR.
F:4Z1
|
N/A |
Annual Cash Flow Conversion Efficiency for Immunovant Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Immunovant Inc from 2018 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $707.45 Million | $-375.87 Million | -0.531x | -53.21% |
| 2024-03-31 | $617.76 Million | $-214.23 Million | -0.347x | +33.20% |
| 2023-03-31 | $362.49 Million | $-188.19 Million | -0.519x | -129.87% |
| 2022-03-31 | $469.82 Million | $-106.11 Million | -0.226x | -6.11% |
| 2021-03-31 | $391.48 Million | $-83.33 Million | -0.213x | +62.47% |
| 2020-03-31 | $94.07 Million | $-53.36 Million | -0.567x | +99.95% |
| 2019-03-31 | $24.55K | $-28.55 Million | -1162.716x | -1456.43% |
| 2018-03-31 | $-1.50 Million | $-128.30 Million | 85.719x | -- |